Skip to main content
News Icon

News categories: Publication

Animal model for studying GPI anchor deficiencies

Intelligence deficit: Conclusion from the mouse to the human being

The group from Peter Krawitz, member of the Cluster of Excellence ImmunoSensation create an animal model for studying GPI anchor deficiencies Impaired intelligence, movement disorders and developmental delays are typical for a group of rare diseases that belong to GPI anchor deficiencies. Researchers from the University of Bonn and the Max Planck Institute for Molecular Genetics used genetic engineering methods to create a mouse that mimics these patients very well. Studies in this animal model suggest that in GPI anchor deficiencies, a gene mutation impairs the transmission of stimuli at the synapses in the brain. This may explain the impairments associated with the disease. The results are now published in the journal "Proceedings of the National Academy of Sciences of the United States of America (PNAS)".

"GPI anchor deficiencies comprise a group of rare diseases that primarily cause intellectual deficits and developmental delays," explains Prof. Dr. Peter Krawitz from the Institute for Genomic Statistics and Bioinformatics at the University Hospital Bonn, who started his research at the Charité - Universitätsmedizin Berlin and continued it at the University Hospital Bonn.


Publication

Miguel Rodríguez de los Santos, Marion Rivalan, Friederike S. David, Alexander Stumpf, Julika Pitsch, Despina Tsortouktzidis, Laura Moreno Velasquez, Anne Voigt, Daniele Mattei, Melissa Long, Guido Vogt, Alexej Knaus, Björn Fischer-Zirnsak, Lars Wittler, Bernd Timmermann, Peter N. Robinson, Denise Horn, Stefan Mundlos, Uwe Kornak, Albert J. Becker, Dietmar Schmitz, York Winter, Peter M. Krawitz: A CRISPR-Cas9-engineered mouse model for GPI anchor deficiency mirrors human phenotype and exhibits hippocampal synaptic dysfunctions, Proceedings of the National Academy of Sciences of the United States of America (PNAS), DOI: 10.1073/pnas.2014481118


Contact

Prof. Dr. med. Dipl. Phys. Peter Krawitz

Institut für Genomische Statistik und Bioinformatik

Universitätsklinikum Bonn

Tel. 0228/28714799

E-mail: pkrawitz@uni-bonn.de

Related news

News Icon

News categories: Publication

Diets need more sustainability

There has been a rapid increase in cardiovascular and metabolic conditions in sub-Saharan Africa. What is the link between sustainable diets that are nutritious, environmentally friendly, economically affordable, and socioculturally acceptable, and cardiometabolic conditions? An international research team led by Prof. Dr. Ina Danquah, Hertz Chair for Innovation for Planetary Health and Director at Center for Development Research (ZEF) at University of Bonn, investigated this question among Ghanaian adults who live in various locations.
View entry
Prof. Christian Strassburg, Direktor der Klinik für Allgemeine Innere Medizin am UKB, mahnt: „Die Abnehmpille ist nicht einfach nur irgendein Spaßfaktor, um jetzt ein bisschen abzunehmen!“

News categories: Publication

Weight-Loss Pill Instead of Injection: Finally, an Easy Way to Lose Weight?

As of September 1, semaglutide will be available in Germany for the treatment of overweight and obesity in tablet form for the first time. The therapy, previously known primarily as a “weight-loss injection,” can now also be taken orally. The market launch is likely to attract considerable interest – but anyone considering treatment should be aware of one thing first: the tablet is not a way to lose a few kilos, but a prescription medication for the treatment of a chronic disease.
View entry
Prof. Matthias Geyer, - together with Prof. Robert P. Fisher from New York, provides an overview of the current state of research on the transcriptional regulation of cyclin-dependent kinases (CDKs) and the prospects for cancer treatment.

News categories: Publication

A Ray of Hope in the Fight Against Cancer

Cancer is the second leading cause of death in Germany. In the search for new therapeutic approaches that target the uncontrolled growth of tumor cells, a class of enzymes known as cyclin-dependent kinases (CDKs) has come into focus. This is because this family of enzymes plays a fundamental role in gene expression and cell division. An overview of the current state of research on the transcriptional regulation of CDKs and the prospects for cancer treatment was compiled by Prof. Matthias Geyer of the UKB in collaboration with Prof. Robert P. Fisher and has now been published.
View entry

Back to the news overview